Demographics of patients receiving CB-derived VST infusions
| Patient ID . | Diagnosis . | Age, y . | Sex . | Weight, kg . | Conditioning regimen . | HLA match (of 6) . | Immunosuppression before VST . | Recipient CMV serostatus . | TNCs from UCB, × 107 . | TNCs/kg of UCB fraction used for primary transplant . |
|---|---|---|---|---|---|---|---|---|---|---|
| ACT-CAT | ||||||||||
| P2891 | Fanconi anemia | 5 | M | 13.0 | Flu/Cy/TBI | 5 | CSA,MMF, steroids | Positive | 161 | 9.9 |
| P3010 | ALL | 2 | M | 11.0 | Flu/Cy/TBI | 5 | CSA, MMF | Positive | 191 | 13.9 |
| P3275 | SCID | 1 | M | 5.2 | Bu/Cy/Flu | 6 | CSA, MMF, steroids | Positive | 121 | 18.8 |
| P3317 | Myelofibrosis | 2 | M | 9.7 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 225 | 18.6 |
| P3457 | JMML | 2 | M | 12.3 | Bu/Cy/Flu | 5 | CSA, MMF | Positive | 185 | 12.0 |
| P3531 | SCID | 1 | M | 6.4 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 129 | 16.0 |
| P3555 | SCID | 1 | M | 8.0 | Bu/Cy/Flu | 6 | CSA, MMF, steroids | Positive | 110 | 11.0 |
| P3923 | AML | 1 | F | 7.0 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 102 | 11.7 |
| P3626 | JMML | 1 | M | 9.0 | Bu/Cy/Flu | 5 | CSA, MMF | Positive | 209 | 18.6 |
| ACT-CAT2 | ||||||||||
| P0020 | AML | 3 | F | 16.7 | Bu/Cy | 5 | CSA, MMF, steroids, ECP | Positive | 103 | 4.9 |
| P0035 | Hurler’s syndrome | 1.1 | F | 8.8 | Bu/Flu/ATG/ rituximab | 4 | CSA, steroids | Positive | 252 | 22.9 |
| P0039 | Infant ALL | 1.9 | M | 12.2 | Flu/Cy/TBI | 6 | CSA, MMF, steroids | Positive | 67 | 4.4 |
| P0067 | Sickle cell disease | 8 | F | 19.8 | Flu/Mel/Thio/alemtuzumab/HU | 6 | CSA, MMF, infliximab, steroids | Positive | 109 | 4.4 |
| P0123 | Sickle cell disease | 4 | M | 16.6 | Flu/Mel/Thio/alemtuzumab/HU | 5 | CSA, tacro, MMF, steroids | Negative | 197 | 9.5 |
| Patient ID . | Diagnosis . | Age, y . | Sex . | Weight, kg . | Conditioning regimen . | HLA match (of 6) . | Immunosuppression before VST . | Recipient CMV serostatus . | TNCs from UCB, × 107 . | TNCs/kg of UCB fraction used for primary transplant . |
|---|---|---|---|---|---|---|---|---|---|---|
| ACT-CAT | ||||||||||
| P2891 | Fanconi anemia | 5 | M | 13.0 | Flu/Cy/TBI | 5 | CSA,MMF, steroids | Positive | 161 | 9.9 |
| P3010 | ALL | 2 | M | 11.0 | Flu/Cy/TBI | 5 | CSA, MMF | Positive | 191 | 13.9 |
| P3275 | SCID | 1 | M | 5.2 | Bu/Cy/Flu | 6 | CSA, MMF, steroids | Positive | 121 | 18.8 |
| P3317 | Myelofibrosis | 2 | M | 9.7 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 225 | 18.6 |
| P3457 | JMML | 2 | M | 12.3 | Bu/Cy/Flu | 5 | CSA, MMF | Positive | 185 | 12.0 |
| P3531 | SCID | 1 | M | 6.4 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 129 | 16.0 |
| P3555 | SCID | 1 | M | 8.0 | Bu/Cy/Flu | 6 | CSA, MMF, steroids | Positive | 110 | 11.0 |
| P3923 | AML | 1 | F | 7.0 | Bu/Cy/Flu | 5 | CSA, MMF, steroids | Positive | 102 | 11.7 |
| P3626 | JMML | 1 | M | 9.0 | Bu/Cy/Flu | 5 | CSA, MMF | Positive | 209 | 18.6 |
| ACT-CAT2 | ||||||||||
| P0020 | AML | 3 | F | 16.7 | Bu/Cy | 5 | CSA, MMF, steroids, ECP | Positive | 103 | 4.9 |
| P0035 | Hurler’s syndrome | 1.1 | F | 8.8 | Bu/Flu/ATG/ rituximab | 4 | CSA, steroids | Positive | 252 | 22.9 |
| P0039 | Infant ALL | 1.9 | M | 12.2 | Flu/Cy/TBI | 6 | CSA, MMF, steroids | Positive | 67 | 4.4 |
| P0067 | Sickle cell disease | 8 | F | 19.8 | Flu/Mel/Thio/alemtuzumab/HU | 6 | CSA, MMF, infliximab, steroids | Positive | 109 | 4.4 |
| P0123 | Sickle cell disease | 4 | M | 16.6 | Flu/Mel/Thio/alemtuzumab/HU | 5 | CSA, tacro, MMF, steroids | Negative | 197 | 9.5 |
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; Bu, busulfan; CSA, cyclosporin A; Cy, cyclophosphamide; ECP, extracorporeal photopheresis; F, female; Flu, fludarabine; HLA, human leukocyte antigen; HU, hydroxyurea; JMML, juvenile myelomonocytic leukemia; M, male; Mel, melphalan; MMF, mycophenolate mofetil; SCID, severe combined immunodeficiency; tacro, tacrolimus; TBI, total body irradiation; Thio, thiotepa; TNC, total nucleated cells; UCB, umbilical cord blood.